Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Atkore Inc. (ATKR), Axsome Therapeutics, Inc. (AXSM), Capricor Therapeutics, Inc. (CAPR), and CTO Realty Growth, Inc. (CTO)
Atkore (NYSE:ATKR) was given a new $71.00 price target on by analysts at Royal Bank Of Canada.
Atkore (NYSE:ATKR) had its "buy" rating reaffirmed by analysts at Roth Mkm.
Atkore (NYSE:ATKR) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..
Atkore Inc (ATKR) Q1 2026 Earnings Call Highlights: Surpassing Expectations with Strong Q1 ... [Yahoo! Finance]